Hill-Rom Holdings Inc. (NYSE:HRC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday.
According to Zacks, “Post a promising third quarter by Hill-Rom, we are upbeat about the company to remain on a solid growth trajectory over the near term. The company’s year-over-year outcome was impressive along with record level of gross margin. Based on several positive catalysts, we expect the company to expand geographically in the coming quarters. Notably, in the last reported quarter, Hill-Rom posted strong growth in both Asia-Pacific and the U.S. While we remain impressed with the company’s increased bottom-line guidance for fiscal 2016, the revenue guidance was quite discouraging. Moreover, Hill-Rom’s persistent poor performance in the International front, especially in the Middle East and Latin America keeps us concerned. Unfortunately no near term improvement can be expected in the existing capital crunch condition that eventually led to economic and political downturns in these economies.”
A number of other equities research analysts have also weighed in on HRC. KeyCorp restated a “buy” rating and issued a $59.00 price objective on shares of Hill-Rom Holdings in a report on Thursday, June 23rd. Morgan Stanley upgraded shares of Hill-Rom Holdings from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $54.00 to $62.00 in a report on Thursday, June 16th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $62.20.
Shares of Hill-Rom Holdings (NYSE:HRC) opened at 61.91 on Wednesday. The stock has a market capitalization of $4.05 billion, a price-to-earnings ratio of 63.76 and a beta of 1.14. The firm has a 50-day moving average of $59.73 and a 200 day moving average of $53.36. Hill-Rom Holdings has a 12-month low of $42.99 and a 12-month high of $62.43.
Hill-Rom Holdings (NYSE:HRC) last announced its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.05. Hill-Rom Holdings had a net margin of 2.47% and a return on equity of 16.62%. The business had revenue of $655.40 million for the quarter, compared to analyst estimates of $647.75 million. During the same period last year, the business earned $0.62 EPS. The company’s revenue was up 38.1% on a year-over-year basis. Equities analysts forecast that Hill-Rom Holdings will post $3.33 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 30th. Investors of record on Friday, September 16th were paid a dividend of $0.17 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $0.68 annualized dividend and a yield of 1.10%. Hill-Rom Holdings’s dividend payout ratio is currently 73.91%.
Large investors have recently made changes to their positions in the company. Zebra Capital Management LLC raised its stake in shares of Hill-Rom Holdings by 30.7% in the first quarter. Zebra Capital Management LLC now owns 20,536 shares of the medical technology company’s stock valued at $1,033,000 after buying an additional 4,822 shares in the last quarter. Acrospire Investment Management LLC acquired a new position in shares of Hill-Rom Holdings during the first quarter valued at about $111,000. BlackRock Institutional Trust Company N.A. increased its position in shares of Hill-Rom Holdings by 270.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 6,359,964 shares of the medical technology company’s stock valued at $319,906,000 after buying an additional 4,642,638 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Hill-Rom Holdings by 0.3% in the first quarter. BlackRock Fund Advisors now owns 2,099,878 shares of the medical technology company’s stock valued at $105,624,000 after buying an additional 6,369 shares during the last quarter. Finally, BlackRock Group LTD increased its position in shares of Hill-Rom Holdings by 46.4% in the first quarter. BlackRock Group LTD now owns 62,884 shares of the medical technology company’s stock valued at $3,163,000 after buying an additional 19,939 shares during the last quarter. Hedge funds and other institutional investors own 83.11% of the company’s stock.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.